TG Therapeutics (TGTX) Misses Q2 EPS by 2c, provides guidance

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $141.1 million versus the consensus estimate of $137.4 million.

GUIDANCE:

TG Therapeutics sees FY2025 revenue of $585 million, versus the consensus of $587.5 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Enhanced Group plans AI health platform launch in 2026
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance